- Home
- NERV vs MNDR Comparison
NERV vs MNDR Comparison
Compare NERV & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- MNDR
- Stock Information
- Founded
- NERV 2007
- MNDR 2016
- Country
- NERV United States
- MNDR Singapore
- Employees
- NERV N/A
- MNDR N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- MNDR
- Sector
- NERV Health Care
- MNDR
- Exchange
- NERV Nasdaq
- MNDR Nasdaq
- Market Cap
- NERV 18.3M
- MNDR 14.7M
- IPO Year
- NERV 2014
- MNDR 2024
- Fundamental
- Price
- NERV $2.20
- MNDR $0.26
- Analyst Decision
- NERV Hold
- MNDR
- Analyst Count
- NERV 1
- MNDR 0
- Target Price
- NERV $5.00
- MNDR N/A
- AVG Volume (30 Days)
- NERV 25.3K
- MNDR 1.7M
- Earning Date
- NERV 11-05-2024
- MNDR 11-23-2024
- Dividend Yield
- NERV N/A
- MNDR N/A
- EPS Growth
- NERV N/A
- MNDR N/A
- EPS
- NERV N/A
- MNDR N/A
- Revenue
- NERV N/A
- MNDR $13,968,535.00
- Revenue This Year
- NERV N/A
- MNDR $188,831.77
- Revenue Next Year
- NERV N/A
- MNDR $76.44
- P/E Ratio
- NERV N/A
- MNDR N/A
- Revenue Growth
- NERV N/A
- MNDR 77.38
- 52 Week Low
- NERV $2.10
- MNDR $0.23
- 52 Week High
- NERV $13.49
- MNDR $29.50
- Technical
- Relative Strength Index (RSI)
- NERV 34.31
- MNDR N/A
- Support Level
- NERV $2.26
- MNDR N/A
- Resistance Level
- NERV $2.43
- MNDR N/A
- Average True Range (ATR)
- NERV 0.16
- MNDR 0.00
- MACD
- NERV -0.01
- MNDR 0.00
- Stochastic Oscillator
- NERV 13.71
- MNDR 0.00
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About MNDR Mobile-health Network Solutions Class A Ordinary Shares
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. They provide their services on its MaNaDr platform, which is accessible via their mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users. The company's revenues are derived mainly from the provision of telemedicine and other services, sale of medicine and medical devices.